Breaking news

WHO’s Historic Agreement: A Major Step Towards Global Pandemic Preparedness

In a groundbreaking move, members of the World Health Organization (WHO) have reached a historic, legally binding agreement aimed at preparing the world for future pandemics. This pact, designed to address the lessons learned from the COVID-19 crisis, sets the stage for a more equitable global response to health emergencies, particularly in the distribution of essential drugs, vaccines, and medical technologies.

The agreement marks a significant milestone in global health governance, especially at a time when multilateral institutions like the WHO are facing considerable financial strain. The United States, which was once the WHO’s largest financial contributor, withdrew from negotiations after President Donald Trump initiated the U.S.’s departure from the organization. Despite this setback, the deal underscores a strong commitment from member states to work together on global health security, with or without U.S. involvement. “This is a historic moment,” said Nina Schwalbe, founder of global health think tank Spark Street Advisors. “It demonstrates that countries are committed to multilateralism and to collective action.”

This agreement, the second of its kind in WHO’s 75-year history (the first being a tobacco control treaty in 2003), focuses on structural inequalities in how pandemic-related health tools are developed and distributed. Article nine of the deal ensures that future pandemic-related drugs, therapeutics, and vaccines will be made globally accessible. It also gives the WHO stronger oversight over medical supply chains and paves the way for local production of vaccines during health crises.

A key challenge in the negotiations was the issue of technology transfer—sharing the knowledge and manufacturing capabilities necessary for lower-income countries to produce their vaccines and treatments. To address this, the agreement mandates that manufacturers allocate at least 20% of their real-time production to the WHO during a pandemic, with a minimum of 10% designated for donation and the rest priced affordably for developing nations.

The deal is not yet finalized, as it must be adopted at the WHO Assembly in May, and some details, such as the annex on Pathogen Access and Benefit Sharing, still require further negotiation. However, once ratified, the agreement will bolster global preparedness, enabling quicker responses to future pandemics and more equitable access to life-saving resources.

As health experts emphasize, the global community must invest in preparedness now to avoid the costly toll of another pandemic. “We can’t afford another pandemic, but we can afford to prevent one,” said Helen Clark, co-chair of The Independent Panel for Pandemic Preparedness. This agreement represents a critical step toward ensuring that the world is better equipped to face future health crises with solidarity, transparency, and a commitment to equity.

China’s Humanoid Robot Boom Faces A Bigger Question: Can These Machines Make Money?

Unitree’s $9 Billion Bet On The Future Of Robotics

China’s humanoid robotics industry is attracting huge investor interest, but as Unitree Robotics prepares for its public debut, questions are growing over whether its robots can move beyond impressive acrobatics and become commercially viable tools.

The Hangzhou-based startup priced its IPO at 150.8 yuan ($22.4) per share, raising $900 million and valuing the company at 61 billion yuan, or about $9 billion. The offering attracted record retail demand on Shanghai’s STAR Market, with the online tranche oversubscribed more than 5,000 times and a winning rate of just 0.018%. Strategic investors included AI startup DeepSeek.

A Unitree-linked pre-IPO perpetual contract was trading at roughly four times the IPO price on Friday, highlighting the speculative interest surrounding the company.

Unitree is known for robots capable of kung fu kicks, backflips and recovering from falls. Yet analysts question whether the technology is ready for large-scale commercial use. “For these humanoid robots, to be honest, they’re fascinating. They can dance and all that, but I’ve never seen them doing any real housework,” said Hao Hong, managing partner of Lotus Asset Management.

In its prospectus, Unitree warned that mass adoption could take longer than expected because robotic hands are still not precise or durable enough for sustained use.

From Acrobatic Robots To Commercial Machines

Even advanced humanoid robots can currently perform only a limited number of tasks and typically operate for a few hours before recharging, according to Dominik Pross, an equity analyst at VP Bank. Most models run for up to four hours, while robots also need to be trained for individual tasks.

“Robots have to be specifically trained for each and every task entrusted to them, even the simplest,” Pross said.

More robotics listings are expected, with Unitree rivals AgiBot and Leju Robotics seeking listings in Hong Kong and Shenzhen. LimX Dynamics founder Will Zhang said last month that “listing is a must.”

China’s Cost Advantage

China’s manufacturing scale has helped it establish a leading position in robotics. Wood Mackenzie expects the global humanoid robot fleet to surpass 10 million units by 2035, while China already accounts for more than 70% of global industrial robot installations and nearly 90% of humanoids deployed last year.

Average humanoid robot prices fell 93% between 2020 and 2025 to $58,000. Unitree’s flagship G1 costs $16,000, while SemiAnalysis estimates that the company has cut the price of its G1 EDU model by more than 45% to $27,300, while maintaining a 67% gross margin.

Falling prices and government support are attracting investment, but analysts say it will take time to prove that humanoid robots can generate strong returns. Unitree’s revenue more than quadrupled last year, although adjusted first-quarter profit fell more than 52% as research and development and marketing spending increased. Nearly three-quarters of its humanoid revenue in the first nine months of 2025 came from research and education, highlighting the gap between demonstrations and widespread commercial use.

“Unlike many early-stage robotics companies, the Unitree story is backed by real revenue growth,” said Jeff Ko, chief analyst at CoinEx. Still, he noted that its $9 billion valuation, at more than 200 times last year’s earnings, reflects significant speculative interest.

Geopolitical Risks

Unitree’s IPO momentum has continued despite growing pressure on Chinese robotics companies. The U.S. moved last month to ban imports of foreign-made humanoid and four-legged robots, potentially exposing Unitree, which generated about 13% of its revenue from the U.S. last year.

Access to Nvidia hardware and software is another risk, as Chinese robotics companies rely on the technology to power their systems. “Chinese robot producers are not yet in a position to do without Western components completely,” Pross said.

China’s control over rare earths used in robot actuators and motors could nevertheless give its manufacturers an advantage, according to Bernstein analyst Dien Wang.

The Bigger Robotics Opportunity

The potential market is attracting major players, including Tesla, whose CEO Elon Musk is expanding production plans for Optimus humanoid robots. At the same time, some researchers argue that the future of robotics will not be limited to humanoids: quadruped and purpose-built robots can be cheaper and more reliable for repetitive industrial tasks, while humanoids may be better suited to unpredictable environments.

For Unitree, the challenge is no longer proving that its robots can perform impressive tricks. It is proving that they can do enough useful work to justify a $9 billion valuation.

Uol
The Future Forbes Realty Global Properties
eCredo
Aretilaw firm

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter